Vertex Pharmaceuticals Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Vertex Pharmaceuticals Inc. filed its 2023 10-K report detailing its fiscal year performance and business operations.</b>

AI Summary

VERTEX PHARMACEUTICALS INC / MA (VRTX) filed a Annual Report (10-K) with the SEC on February 15, 2024. Vertex Pharmaceuticals Inc. filed its 2023 Form 10-K on February 15, 2024. The filing covers the fiscal year ending December 31, 2023. The company's principal business is in Pharmaceutical Preparations (SIC 2834). Vertex Pharmaceuticals Inc. is incorporated in Massachusetts. The company's principal executive offices are located at 50 Northern Avenue, Boston, MA.

Why It Matters

For investors and stakeholders tracking VERTEX PHARMACEUTICALS INC / MA, this filing contains several important signals. This 10-K filing provides a comprehensive overview of Vertex Pharmaceuticals' financial health, operational strategies, and risk factors for the fiscal year 2023, crucial for investors and stakeholders to assess the company's performance and future outlook. The detailed financial statements and disclosures within the 10-K allow for a thorough analysis of Vertex's revenue streams, profitability, and balance sheet strength, enabling informed investment decisions.

Risk Assessment

Risk Level: medium — VERTEX PHARMACEUTICALS INC / MA shows moderate risk based on this filing. The company operates in the highly regulated pharmaceutical industry, facing risks related to drug development, clinical trials, regulatory approvals, and market competition, as detailed in its risk factors section.

Analyst Insight

Investors should review the detailed risk factors and financial performance metrics in the 10-K to assess Vertex Pharmaceuticals' long-term growth prospects and potential challenges.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting period end date)
• 2024-02-15 — Filing Date (Date the 10-K was filed)
• 0000875320 — Central Index Key (Unique identifier for the filer)
• 2834 — Standard Industrial Classification (Industry code for Pharmaceutical Preparations)

Key Players & Entities

• VERTEX PHARMACEUTICALS INC / MA (company) — Filer name
• 0000875320 (company) — Central Index Key
• 2834 (company) — Standard Industrial Classification
• MA (company) — State of Incorporation
• 6173416393 (company) — Business Phone
• 20231231 (date) — Fiscal Year End
• 20240215 (date) — Filing Date
• 000-19319 (company) — SEC File Number

FAQ

Risk Factors

• Regulatory Risks [high — regulatory]: The company is subject to extensive government regulation, including the FDA, which can impact product development, manufacturing, and marketing.
• Competition [high — market]: Vertex faces intense competition from other pharmaceutical companies, which could affect market share and pricing.
• Research and Development [high — operational]: The success of Vertex relies heavily on its ability to successfully develop and commercialize new drugs, which is inherently uncertain.
• Intellectual Property [medium — financial]: Protection of intellectual property is critical; patent expirations or challenges could adversely affect revenue.
• Product Liability [medium — legal]: The company faces potential product liability claims related to its pharmaceutical products.

Key Dates

• 2024-02-15: 10-K Filing — Annual report filing for fiscal year 2023
• 2023-12-31: Fiscal Year End — End date of the reporting period

Key Financial Figures

• $0.01 — ange on Which Registered Common Stock, $0.01 Par Value Per Share VRTX The Nasdaq Glo

Filing Documents

• vrtx-20231231.htm (10-K) — 2603KB
• a10k_2023-exhibit107.htm (EX-10.7) — 52KB
• a10k_2023-exhibit1036.htm (EX-10.36) — 4KB
• a10k_2023-exhibit211.htm (EX-21.1) — 12KB
• a10k_2023-exhibit231.htm (EX-23.1) — 5KB
• a10k_2023-exhibit311.htm (EX-31.1) — 10KB
• a10k_2023-exhibit312.htm (EX-31.2) — 10KB
• a10k_2023-exhibit321.htm (EX-32.1) — 6KB
• a10k_2023-exhibit971.htm (EX-97.1) — 27KB
• vrtx-20231231_g1.jpg (GRAPHIC) — 45KB
• vrtx-20231231_g10.gif (GRAPHIC) — 12KB
• vrtx-20231231_g2.jpg (GRAPHIC) — 70KB
• vrtx-20231231_g3.jpg (GRAPHIC) — 87KB
• vrtx-20231231_g4.jpg (GRAPHIC) — 121KB
• vrtx-20231231_g5.jpg (GRAPHIC) — 198KB
• vrtx-20231231_g6.jpg (GRAPHIC) — 87KB
• vrtx-20231231_g7.jpg (GRAPHIC) — 85KB
• vrtx-20231231_g8.jpg (GRAPHIC) — 100KB
• vrtx-20231231_g9.jpg (GRAPHIC) — 287KB
• 0000875320-24-000062.txt (&nbsp;) — 16748KB
• vrtx-20231231.xsd (EX-101.SCH) — 90KB
• vrtx-20231231_cal.xml (EX-101.CAL) — 163KB
• vrtx-20231231_def.xml (EX-101.DEF) — 453KB
• vrtx-20231231_lab.xml (EX-101.LAB) — 1171KB
• vrtx-20231231_pre.xml (EX-101.PRE) — 804KB
• vrtx-20231231_htm.xml (XML) — 2426KB

Business

Business 1 Information about our Executive Officers 28 Item 1A.

Risk Factors

Risk Factors 31 Item 1B. Unresolved Staff Comments 62 Item 1C . Cybersecurity 62 Item 2.

Properties

Properties 63 Item 3.

Legal Proceedings

Legal Proceedings 63 Item 4. Mine Safety Disclosures 63 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 64 Item 6. [Reserved] 65 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 66 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 84 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 85 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 85 Item 9A.

Controls and Procedures

Controls and Procedures 85 Item 9B. Other Information 88 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 88 PART III Item 10. Directors, Executive Officers and Corporate Governance 89 Item 11.

Executive Compensation

Executive Compensation 89 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 89 Item 13. Certain Relationships and Related Transactions, and Director Independence 89 Item 14. Principal Accountant Fees and Services 89 PART IV Item 15. Exhibits and Financial Statement Schedules 90 Item 16. Form 10-K Summary 92

Signatures

Signatures 93 "Vertex," "we," "us" and "our" as used in this Annual Report on Form 10-K refer to Vertex Pharmaceuticals Incorporated, a Massachusetts corporation, and its subsidiaries. "VERTEX ," "KALYDECO ," "ORKAMBI ," "SYMDEKO ," "SYMKEVI ," "TRIKAFTA ," "KAFTRIO ," and "CASGEVY" are registered trademarks of Vertex. Other brands, names and trademarks contained in this Annual Report on Form 10-K are the property of their respective owners. We use the brand name for our products when we refer to the product that has been approved and with respect to the indications on the approved label. Otherwise, including in discussions of our cystic fibrosis, sickle cell disease, and beta thalassemia development programs, we refer to our product candidates by their scientific (or generic) name or VX developmental designation. This Annual Report on Form 10-K contains forward-looking statements. Words such as "anticipates," "may," "forecasts," "expects," "intends," "plans," "potentially," "believes," "seeks," "estimates," variations of such words and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Please refer to "Special Note Regarding Forward-Looking Statements" set forth in Part I, Item 1A, for a discussion of our forward-looking statements and the related risks and uncertainties of such statements. PART I

BUSINESS

ITEM 1. BUSINESS OVERVIEW We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. We have four approved medicines that treat the underlying cause of cystic fibrosis ("CF"), a life-threatening genetic disease, and one approved therapy that treats severe sickle cell disease ("SCD") and transfusion dependent beta thalassemia ("TDT"), life shortening inherited blood disorders. Our pipeline includes clinical-stage programs in CF, sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1 and alpha-1 antitrypsin deficiency. Our goal in CF is to develop treatment regimens that will provide benefits to all people with CF and will enhance the benefits currently provided to people taking our medicines. Our marketed medicines that treat people with CF are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Collectively, our four marketed CF medicines are being used to treat nearly three quarters of the approximately 92,000 people with CF in North America, Europe and Australia. Through label expansions, approval of new medicines, and expanded reimbursement, we are focused on increasing the number of people with CF who are eligible and able to receive our medicines. We are evaluating our current medicines in additional patient populations, including younger children, with the goal of having small molecule treatments for all people who have at least one mutation in their cystic fibrosis transmembrane conductance regulator ("CFTR") gene that is responsive to our CFTR modulators. We have completed Phase 3 development of a triple combination of vanzacaftor/tezacaftor/deutivacaftor, which has demonstrated the potential to provide additional clinical bene

View Full Filing

View this 10-K filing on SEC EDGAR